ClinicalTrials.gg
CompletedNCT01676220EDITION IIIUpdated Jun 24, 2015Results posted

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

A Phase 3 interventional study of HOE901-U300 (new formulation of insulin glargine) and Lantus (insulin glargine) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 217 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
878
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
14th of 175
878 · median 253
Started
2012
with 4 others
Phase 3
60 of 176
1 open now
Registered
100th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment of the 175 interventional ones that give a count, is one of 5 that started in 2012, is one of 60 in phase 3, and was the 100th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus

Secondary Objectives:

To compare a new formulation of insulin glargine and Lantus in terms of:

  • occurrence of nocturnal hypoglycemia
Read the detailed description

The maximum study duration was up to approximately 54 weeks per participant, consisting of:

  • Up to 2 week screening period; it can be exceptionally extended of up to one additional week
  • 6-month comparative efficacy and safety treatment period
  • 6-month comparative safety extension period
  • 2-day post-treatment safety follow-up period
03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with type 2 diabetes mellitus inadequately controlled with non-insulin antihyperglycemic drug(s);
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • less than (\<) 7.0% (\< 53 millimole per mole [mmol/mol]) or greater than (>) 11% (> 97 mmol/mol)
  • History of type 2 diabetes mellitus for less than 1 year before screening
  • Less than 6 months before screening with non-insulin antihyperglycemic treatment
  • Change in dose of non-insulin antihyperglycemic treatment in the last 3 month before screening
  • Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit and/or initiation of Glucagon-like peptide-1 (GLP-1) receptor agonist in the last 6 months before screening visit
  • Participants receiving only non-insulin antihyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinide (Note: non-insulin antihyperglycemic drugs not approved for combination with insulin, sulfonylurea and glinide are to be discontinued at baseline)
  • Current or previous insulin use except for a maximum of 8 consecutive days (for example, acute illness, surgery) during the last year prior to screening
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (for example, laser, surgical treatment or injectable drugs) during the study period

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
878 participants (actual)

Study arms

  • Experimental
    HOE901-U300

    Drug: HOE901-U300 (new formulation of insulin glargine)

  • Active comparator
    Lantus

    Drug: Lantus (insulin glargine)

Interventions

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).

    Also known as: Lantus

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Month 6 Endpoint

    Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6

    Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]). Only nocturnal hypoglycemia occurring before initiation of rescue therapy were considered in the analysis. Week 9 and Month 6 value correspond to the observed value at Week 9 and Month 6 visit respectively.

    Time frame: Week 9 Up to Month 6

  2. Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint

    Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Except for baseline value average of preinjection SMPG was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

  3. Variability of Preinjection SMPG at Month 6 Endpoint

    Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Month 6

  4. Percentage of Participants With HbA1c <7% at Month 6

    Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

    Time frame: Month 6

  5. Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint

    Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

  6. Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6

    Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

    Time frame: Month 6

  7. Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6

    Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 8-point SMPG profiles measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

    Time frame: Baseline, Month 6

  8. Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint

    Change in 24-hour average of 8-point SMPG profile. 8-point SMPG was assessed at: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 24-hour average 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

  9. Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint

    Variability is assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 5 measurements of the 8-point profiles. Only variability of 24-hour 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

  10. Change in Daily Basal Insulin Dose From Baseline to Month 6

    Only insulin dose measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

    Time frame: Baseline, Month 6

  11. Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

    DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only DTSQ total score measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

    Time frame: Baseline, Month 6

  12. Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12

    Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

    Time frame: Up to 12 months

07

Results

Posted Apr 23, 2015

Participant flow

A total of 1396 participants were screened, of whom 518 participants were screen failure and 878 participants were randomized.

Participant flow — Overall Study
MilestoneHOE901-U300Lantus (Insulin Glargine)
Started439439
Treated435438
Modified intent-to-treat population432430
Completed337314
Not completed102125
Withdrew: Randomized but not treated41
Withdrew: Adverse event108
Withdrew: Lack of efficacy25
Withdrew: Protocol violation1112
Withdrew: Received rescue therapy1422
Withdrew: Personal reason3445
Withdrew: Lost to follow-up1118
Withdrew: Selection criterion/protocol violation99
Withdrew: Site closure/site withdrawal14
Withdrew: Perceived lack of efficacy31
Withdrew: Non serious hypoglycemia20
Withdrew: No more need of insulin10

Outcome measures

PrimaryChange in HbA1c From Baseline to Month 6 Endpoint

Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of hemoglobin
Change in HbA1c From Baseline to Month 6 Endpoint
percentage of hemoglobinHOE901-U300Lantus
Change in HbA1c From Baseline to Month 6 Endpoint-1.42 ± 0.047-1.46 ± 0.048
Statistical analysis
  • HOE901-U300 vs Lantus · Least squares (ls) mean difference: 0.04 · 95% CI -0.090 to 0.174
SecondaryPercentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6

Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]). Only nocturnal hypoglycemia occurring before initiation of rescue therapy were considered in the analysis. Week 9 and Month 6 value correspond to the observed value at Week 9 and Month 6 visit respectively.

Time frame:
Week 9 Up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6
percentage of participantsHOE901-U300Lantus
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 615.517.4
Statistical analysis
  • HOE901-U300 vs Lantus · Cochran-Mantel-Haenszel · p = 0.4536 · Risk ratio (rr): 0.89 · 95% CI 0.66 to 1.20
SecondaryChange in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint

Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Except for baseline value average of preinjection SMPG was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
Change in Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint-2.16 ± 0.162-2.33 ± 0.156
Statistical analysis
  • HOE901-U300 vs Lantus · Ls mean difference: 0.17 · 95% CI -0.275 to 0.605
SecondaryVariability of Preinjection SMPG at Month 6 Endpoint

Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only preinjection SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Month 6
Reported as:
Least squares mean · percentage of mean
Variability of Preinjection SMPG at Month 6 Endpoint
percentage of meanHOE901-U300Lantus
Variability of Preinjection SMPG at Month 6 Endpoint18.70 ± 0.50218.33 ± 0.521
SecondaryPercentage of Participants With HbA1c <7% at Month 6

Only HbA1c measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7% at Month 6
percentage of participantsHOE901-U300Lantus
Percentage of Participants With HbA1c <7% at Month 643.142.1
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint

Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint-3.41 ± 0.103-3.80 ± 0.105
SecondaryPercentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6

Only FPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 6
percentage of participantsHOE901-U300Lantus
Percentage of Participants With FPG <5.6 mmol/L (100 mg/dL) at Month 626.229.5
SecondaryChange in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6

Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 8-point SMPG profiles measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

Time frame:
Baseline, Month 6
Reported as:
Mean · mmol/L
Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6
mmol/LHOE901-U300Lantus
03:00 at Night Plasma Glucose (n=281,277)-2.63 ± 3.24-3.01 ± 3.75
Pre-Breakfast Plasma Glucose (n=292,286)-3.28 ± 2.72-3.72 ± 2.96
2 Hours After Breakfast Plasma Glucose (n=278,278)-3.69 ± 3.65-4.08 ± 4.03
Pre-Lunch Plasma Glucose (n=289,281)-2.58 ± 3.39-3.39 ± 3.76
2 Hours After Lunch Plasma Glucose (n=280,269)-2.19 ± 3.88-3.13 ± 3.77
Pre-Dinner Plasma Glucose (n=291,285)-2.57 ± 3.49-2.43 ± 3.79
2 Hours After Dinner Plasma Glucose (n=282,269)-2.36 ± 3.89-2.33 ± 4.03
Bedtime Plasma Glucose (n=249,249)-2.19 ± 3.75-2.26 ± 3.66
SecondaryChange in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint

Change in 24-hour average of 8-point SMPG profile. 8-point SMPG was assessed at: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only 24-hour average 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
Change in 24-hour Average 8-point SMPG Profile From Baseline to Month 6 Endpoint-2.72 ± 0.088-2.90 ± 0.089
SecondaryChange in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint

Variability is assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 5 measurements of the 8-point profiles. Only variability of 24-hour 8-point SMPG measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of mean
Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint
percentage of meanHOE901-U300Lantus
Change in Variability of 24 Hour Average 8-point SMPG Profiles From Baseline to Month 6 Endpoint1.53 ± 0.6431.41 ± 0.647
SecondaryChange in Daily Basal Insulin Dose From Baseline to Month 6

Only insulin dose measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 value corresponds to the observed value at Month 6 visit.

Time frame:
Baseline, Month 6
Reported as:
Mean · U/kg
Change in Daily Basal Insulin Dose From Baseline to Month 6
U/kgHOE901-U300Lantus
Change in Daily Basal Insulin Dose From Baseline to Month 60.43 ± 0.290.34 ± 0.24
SecondaryChange in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only DTSQ total score measurements performed before initiation of rescue therapy were considered in the analysis. Month 6 Endpoint is either the observed value at Month 6 visit or value retrieved according to time windows.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · units on a scale
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
units on a scaleHOE901-U300Lantus
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint4.89 ± 0.2465.12 ± 0.251
SecondaryPercentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12

Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

Time frame:
Up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12
percentage of participantsHOE901-U300Lantus
Any Hypoglycemia Event: All Hypoglycemia58.963.2
Severe Hypoglycemia: All Hypoglycemia1.42.1
Documented Symptomatic: All Hypoglycemia39.144.1
Asymptomatic: All Hypoglycemia41.646.8
Probable Symptomatic: All Hypoglycemia3.23.0
Relative: All Hypoglycemia10.611.6
Severe and/or Confirmed: All Hypoglycemia56.361.2
Any Hypoglycemia Event: Nocturnal Hypoglycemia27.630.1
Severe Hypoglycemia: Nocturnal Hypoglycemia0.00.7
Documented Symptomatic: Nocturnal Hypoglycemia18.620.8
Asymptomatic: Nocturnal Hypoglycemia13.316.0
Probable Symptomatic: Nocturnal Hypoglycemia0.70.0
Relative: Nocturnal Hypoglycemia4.43.2
Severe and/or Confirmed: Nocturnal Hypoglycemia25.329.5

Adverse events

Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HOE901-U300—35/435 (8%)115/435 (26.4%)
Lantus—39/438 (8.9%)107/438 (24.4%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventHOE901-U300Lantus
Abdominal painGastrointestinal disorders0/4353/438
Atrial fibrillationCardiac disorders2/4351/438
Coronary artery diseaseCardiac disorders2/4350/438
Non-cardiac chest painGeneral disorders2/4350/438
DiverticulitisInfections and infestations2/4350/438
NephrolithiasisRenal and urinary disorders2/4350/438
Acute myocardial infarctionCardiac disorders1/4352/438
Angina pectorisCardiac disorders1/4352/438
Gastrointestinal haemorrhageGastrointestinal disorders0/4352/438
OsteoarthritisMusculoskeletal and connective tissue disorders1/4352/438
Most frequent other events
Most frequent other events
EventHOE901-U300Lantus
NasopharyngitisInfections and infestations41/43547/438
Upper respiratory tract infectionInfections and infestations45/43534/438
HeadacheNervous system disorders36/43522/438
SinusitisInfections and infestations11/43523/438

Baseline characteristics

Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)HOE901-U300LantusTotal
Mean58.2 ± 9.957.2 ± 10.357.7 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)HOE901-U300LantusTotal
Female186185371
Male253254507
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter)HOE901-U300LantusTotal
Mean32.8 ± 6.933.2 ± 6.633.0 ± 6.7
Duration of Diabetes
Duration of Diabetes(years)HOE901-U300LantusTotal
Mean10.11 ± 6.499.57 ± 6.229.84 ± 6.36
Basal Insulin Daily Dose
Basal Insulin Daily Dose(units per kilogram (U/kg))HOE901-U300LantusTotal
Mean0.193 ± 0.0270.193 ± 0.0340.193 ± 0.031
Glycated Hemoglobin A1c (HbA1c)
Glycated Hemoglobin A1c (HbA1c)(participants)HOE901-U300LantusTotal
Less Than (<) 8%141142283
Greater Than or Equal to (>=) 8%298297595
08

Study locations

217 sites
  • Investigational Site Number 840324
    Montgomery, Alabama 36109, United States
  • Investigational Site Number 840273
    Chandler, Arizona 85224, United States
  • Investigational Site Number 840217
    Mesa, Arizona 85206, United States
  • Investigational Site Number 840220
    Peoria, Arizona 85050, United States
  • Investigational Site Number 840211
    Phoenix, Arizona 85028, United States
  • Investigational Site Number 840207
    Phoenix, Arizona 85050, United States
  • Investigational Site Number 840264
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840234
    Tempe, Arizona, United States
  • Investigational Site Number 840304
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840347
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840244
    Escondido, California 92025, United States
  • Investigational Site Number 840257
    Fresno, California 93720, United States
  • Investigational Site Number 840213
    Greenbrae, California 94904, United States
  • Investigational Site Number 840267
    Huntington Beach, California 92648, United States
  • Investigational Site Number 840230
    La Jolla, California 92037, United States
  • Investigational Site Number 840235
    La Mesa, California 91942, United States
  • Investigational Site Number 840274
    La Mesa, California 91942, United States
  • Investigational Site Number 840222
    Long Beach, California 90806, United States
  • Investigational Site Number 840243
    Palm Springs, California 92262, United States
  • Investigational Site Number 840250
    Spring Valley, California 91978, United States
  • Investigational Site Number 840209
    Temecula, California 92591, United States
  • Investigational Site Number 840297
    Torrance, California 90502, United States
  • Investigational Site Number 840272
    Tustin, California 92780, United States
  • Investigational Site Number 840223
    Walnut Creek, California 94598, United States
  • Investigational Site Number 840249
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number 840331
    Denver, Colorado 80212, United States
  • Investigational Site Number 840299
    Boca Raton, Florida 33432, United States
  • Investigational Site Number 840285
    Boynton Beach, Florida 33472, United States
  • Investigational Site Number 840221
    Bradenton, Florida 34208, United States
  • Investigational Site Number 840233
    Clearwater, Florida 33765, United States
  • Investigational Site Number 840212
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840266
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840204
    Hialeah, Florida 33012, United States
  • Investigational Site Number 840248
    Hollywood, Florida 33021, United States
  • Investigational Site Number 840226
    Jacksonville, Florida 32205, United States
  • Investigational Site Number 840318
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840224
    Jacksonville, Florida 32258, United States
  • Investigational Site Number 840337
    Miami Beach, Florida 33141, United States
  • Investigational Site Number 840228
    Miami, Florida 33144, United States
  • Investigational Site Number 840238
    Miami, Florida 33144, United States
  • Investigational Site Number 840302
    Miami, Florida 33176, United States
  • Investigational Site Number 840227
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840303
    North Miami Beach, Florida 33162, United States
  • Investigational Site Number 840225
    Ocala, Florida 34471, United States
  • Investigational Site Number 840291
    Orlando, Florida 32804, United States
  • Investigational Site Number 840316
    Orlando, Florida 32806, United States
  • Investigational Site Number 840216
    Oviedo, Florida 32765, United States
  • Investigational Site Number 840332
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840288
    Pembroke Pines, Florida 33028, United States
  • Investigational Site Number 840325
    Port Charlotte, Florida 33952, United States
  • Investigational Site Number 840309
    St. Petersburg, Florida 33716, United States
  • Investigational Site Number 840251
    Tampa, Florida 33603, United States
  • Investigational Site Number 840339
    West Palm Beach, Florida 33401, United States
  • Investigational Site Number 840245
    Atlanta, Georgia 30308, United States
  • Investigational Site Number 840323
    Stockbridge, Georgia 30281, United States
  • Investigational Site Number 840236
    Honolulu, Hawaii 96814, United States
  • Investigational Site Number 840283
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840278
    Chicago, Illinois 60607, United States
  • Investigational Site Number 840320
    Chicago, Illinois 60612, United States
  • Investigational Site Number 840276
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840314
    Avon, Indiana 46123, United States
  • Investigational Site Number 840317
    Avon, Indiana 46123, United States
  • Investigational Site Number 840214
    Des Moines, Iowa 50314, United States
  • Investigational Site Number 840232
    Overland Park, Kansas 66210, United States
  • Investigational Site Number 840287
    Topeka, Kansas 66606, United States
  • Investigational Site Number 840344
    Lexington, Kentucky 40503, United States
  • Investigational Site Number 840231
    Murray, Kentucky 42003, United States
  • Investigational Site Number 840348
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840290
    New Orleans, Louisiana 70119, United States
  • Investigational Site Number 840208
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840301
    Rockville, Maryland 20852, United States
  • Investigational Site Number 840289
    Fall River, Massachusetts 02720, United States
  • Investigational Site Number 840253
    Haverhill, Massachusetts 1830, United States
  • Investigational Site Number 840270
    Madison Heights, Michigan 48071, United States
  • Investigational Site Number 840300
    Omaha, Nebraska 68105, United States
  • Investigational Site Number 840210
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840263
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840349
    Las Vegas, Nevada 89117, United States
  • Investigational Site Number 840201
    Las Vegas, Nevada 89119, United States
  • Investigational Site Number 840256
    Las Vegas, Nevada 89148, United States
  • Investigational Site Number 840306
    Hamilton, New Jersey 08619, United States
  • Investigational Site Number 840203
    Sea Girt, New Jersey 08750, United States
  • Investigational Site Number 840295
    Sicklerville, New Jersey 08081, United States
  • Investigational Site Number 840269
    Albuquerque, New Mexico 87106, United States
  • Investigational Site Number 840310
    New Hyde Park, New York 11042, United States
  • Investigational Site Number 840247
    Asheville, North Carolina 28803, United States
  • Investigational Site Number 840296
    Greensboro, North Carolina 27408, United States
  • Investigational Site Number 840275
    Morganton, North Carolina 28655, United States
  • Investigational Site Number 840330
    Cleveland, Ohio 44122, United States
  • Investigational Site Number 840307
    Columbus, Ohio 43213, United States
  • Investigational Site Number 840229
    Norman, Oklahoma 73069, United States
  • Investigational Site Number 840219
    Bend, Oregon 97701, United States
  • Investigational Site Number 840240
    Philadelphia, Pennsylvania 19139, United States
  • Investigational Site Number 840308
    Tipton, Pennsylvania 16684, United States
  • Investigational Site Number 840252
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840237
    Spartanburg, South Carolina 29303, United States
  • Investigational Site Number 840294
    Dakota Dunes, South Dakota 57049, United States
  • Investigational Site Number 840260
    Bristol, Tennessee 37620, United States
  • Investigational Site Number 840262
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840342
    Corpus Christi, Texas 78404, United States

Showing the first 100 of 217 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12. PubMed 25641260 ↗
  • Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2020 Apr;46(2):110-118. doi: 10.1016/j.diabet.2018.10.002. Epub 2018 Oct 23. PubMed 30366067 ↗
  • Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2. PubMed 30160030 ↗
  • Yale JF, Pettus JH, Brito-Sanfiel M, Lavalle-Gonzalez F, Merino-Trigo A, Stella P, Chevalier S, Buzzetti R. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS One. 2018 Jan 25;13(1):e0190579. doi: 10.1371/journal.pone.0190579. eCollection 2018. PubMed 29370218 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Sep 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 7 months after primary completion. A results delay was requested in Nov 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2012
First posted
Aug 30, 2012
Start
Aug 2012
Primary completionActual
Sep 2013
CompletionActual
Mar 2014
Results delay requested
Nov 14, 2014
Results first posted
Apr 23, 2015
Last update
Jun 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01676220
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 30, 2012
Start date
Aug 2012
Primary completion
Sep 2013
Completion
Mar 2014
Results posted
Apr 23, 2015
Last update
Jun 24, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion